Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors - Ren, Xiaojia; Boriero, Diana; Chaiswing, Luksana; Bondada, Subbarao; St. Clair, Daret K.; Butterfield, D. Allan (Biochimica et biophysica acta. Molecular basis of disease, 2019)
Keywords: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Blood-brain barrier; Brain - drug effects; Brain - pathology; Brain - physiopathology; Cancer Survivors - psychology; Cancer Survivors - statistics & numerical data; Chemotherapy-induced cognitive impairment; Cognitive Dysfunction - chemically induced; Cognitive Dysfunction - physiopathology; Humans; Memory - drug effects; Mitochondrial dysfunction; Models, Biological; Neoplasms - drug therapy; Neoplasms - physiopathology; Neoplasms - psychology; Oxidative damage; Oxidative Stress - drug effects; Quality of Life; TNF-alpha; APE1/APEX1; BBB; TNF-alpha; OGG1; MDA; COMT; NF-κB; Blood-brain barrier; RNS; iNOS; JAK2; AD; cyt c; Dox; IL-1β; IL-6; AP; NOR; P-pg; ROS; TLR4; FDA; O2; COX-2; MRI; CNS; DTX; MDR1; CICI; SNP; BCNU; ApoA1; Chemotherapy-induced cognitive impairment; APOE; GCEE; GSH; ABCA1; PGE2; MRP1; Mitochondrial dysfunction; BDNF; Oxidative damage; STAT3; 8-oxoG; BER; GIGT; NAC; PC; PD; TNF-α; MnSOD; HNE; PET